Recent News

• 04.21.2025 - Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
• 04.21.2025 - Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
• 04.21.2025 - Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
• 04.17.2025 - Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
• 04.17.2025 - Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
• 04.17.2025 - Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
• 04.07.2025 - Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
• 04.07.2025 - Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
• 04.07.2025 - Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
• 03.31.2025 - Zevra Therapeutics Files Preliminary Proxy

Recent Filings

• 04.21.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.21.2025 - DEFC14A Definitive proxy statement, contested solicitations
• 04.21.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.16.2025 - PRRN14A Non-management revised preliminary proxy soliciting materials, contested and otherwise
• 04.10.2025 - PREC14A Preliminary proxy statements, contested solicitations
• 04.07.2025 - EX-99.1 EX-99.1
• 04.07.2025 - 8-K Current report
• 04.07.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material